Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires.
AbbVie’s top-selling therapeutic Humira for the treatment of arthritis has seen a market shift towards biosimilars of the monoclonal antibody (mAb) launched at discounted prices compared to Humira. From pharmaceutical giants such as Sandoz and Organon/Samsung Bioepis entering the mAb market in the last week, the availability of treatment options marks a significant milestone for accessible treatment options for millions of autoimmune disease patients.
The partnership between Organon and Samsung Bioepis launched the biosimilar Hadlima in the US, listed at an 85% discount rate of Humira at USD $1038 per month compared to Humira’s USD $6922 per month. Hadlima functions as a tumour necrosis factor (TNF) blocker for the indications of rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, and other inflammatory diseases. Other biosimilars released in the past week include Sandoz’s Hyrimoz, at a 5% discount to Humira’s price, and an unbranded version at an 81% discount. Boehringer Ingelheim also released Cyltezo at a 5–7% price drop. Amgen was the first company to release a biosimilar of Humira in the US earlier this year at a 5% and 55% discount, depending on the purchaser.
Though Organon and Samsung Bioepis did not confirm whether pharmacy benefit managers (PBMs), who negotiate insurance coverage for large employers and health insurance plans, had secured reimbursement of Hadlima, healthcare experts had previously stated their expectations that some biosimilars of Humira would debut with a discount in order to appeal to these PBMs.
Unlike generics, biosimilars are not necessarily exact copies of an innovative drug product whose patent has expired. While both are often touted as cheaper versions of name-brand drugs, biosimilars may achieve the same therapeutic and clinical result without exact duplication – they are drugs that are ‘highly similar’. Additionally, biosimilars aim to model the effects of drug products made from living organisms as therapeutic ingredients while generics are copies of synthetic drugs.
CEO of Organon Kevin Ali stated of the launch: “As the largest loss-of-exclusivity event in pharmaceutical history, this is a singular moment for the US healthcare system to embrace biosimilars. Every stakeholder should be invested in the success of this market to realise the value biosimilars can create for patients, providers, and the US healthcare economy. We are thrilled to now provide Hadlima in the US at a more affordable cost and expand much-needed access to adalimumab.”
At least nine drug products considered to be clinical copies of Humira are expected to be released in the US by the end of 2023, with companies such as Pfizer and Celltrion announcing plans for their own biosimilar launches.
Sources
1. Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount [Accessed July 3, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/organon-samsung-bioepis-launch-copycat-arthritis-drug-humira-85-discount-2023-07-01/
2. Sandoz launches rival version of AbbVie’s arthritis drug Humira [Accessed July 3, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/sandoz-launches-rival-version-abbvies-arthritis-drug-humira-2023-07-01/
3. Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMATM (adalimumab-bwwd) in Multiple Presentations Consistent with Originator [Accessed July 3, 2023] https://www.organon.com/news/organon-samsung-bioepis-announce-us-launch-of-humira-biosimilar-hadlima-adalimumab-bwwd-in-multiple-presentations-consistent-with-originator/
Related News
-
News Pharma CEOs write open letter calling suppliers to commit to sustainability
Several big pharma companies have added their names to a letter challenging suppliers in the healthcare industry to pledge to sustainability targets. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News Women in Pharma: Gearing up for systemic change
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Delivering on mRNA-based therapeutics: innovations in applications and packaging
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet... -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts. -
News Novo Nordisk announces expansion of Hillerød API manufacturing facility
Novo Nordisk will invest 15.9 billion Danish kroner into the expansion of their existing API manufacturing facility.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance